China Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering (NGS [Kits {Library Prep, QC, DNA Extraction}, Systems], PCR, Microarrays {Protein, DNA, RNA, Tissue}, Software) Application (Research, Clinical), End User-Forecast to 2031

The China Neurogenomics Market was valued at $136.4 million in 2023. This market is expected to reach $562.1 million by 2031 from an estimated $162.1 million in 2024, at a CAGR of 19.4% during the forecast period from 2024 to 2031.

China Neurogenomics Market Size & Forecast

The growth of this market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for gene sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of neurological diseases, technological advancements in neurogenomics products, and government initiatives promoting the use of sequencing in clinical & research applications. However, high prices of neurogenomics products, the low chances of identifying positive actionable mutations for precision medicine, and ethical & legal issues related to sequencing-based diagnosis is expected to restrain the growth of this market.

The increasing adoption of targeted therapies, emerging economies, and rising awareness regarding neurological disorders are expected to create market growth opportunities. Moreover, the dynamic regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the shortage of sequencing professionals in the country, and the high capital investments required for sequencing setups is a prominent trend in the China Neurogenomics Market.

China Neurogenomics Market Growth Drivers

The Growing Utilization of Advanced Sequencing Technologies in Disease Diagnostics & Precision Medicine

Precision medicine is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup, also considering genetic changes resulting from a disease and lifestyle habits. It is an emerging disease treatment & prevention approach that considers variability in genes, environments, and lifestyles among individuals. Precision medicine can reduce the need for guesswork (trial and error in medication depending on how the medication affects the patient’s symptoms), help physicians overcome challenges related to variable diagnostic ability, and aid the development of treatment strategies based on generalized demographics. Moreover, precision medicine using advanced provides a more holistic view of an individual’s health. In clinical workflows of neurogenomics, precision medicine facilitates more predictive and preventive care through targeted therapies. Major advantages of precision medicine include reductions in trial & error prescriptions, avoidance of adverse drug reactions, increased patient adherence to treatment due to fewer side effects, a decrease in the prescription of unnecessary drugs to non-responder patients, optimization of drug development costs, better control over.      

Increasing Prevalence of Neurological Disorders

China accounts for approximately 17% of the global disease burden related to neurological, mental, and substance use disorders. The country is rapidly undergoing a societal change, facing challenges in reducing the disease burden of psychiatric disorders. The increasing cases of neurological disorders have increased the burden on the country’s healthcare system, further boosting the demand for more advanced diagnostic solutions. For instance, China faces the greatest burden of stroke globally. According to results from the Global Burden of Disease Study 2019, there were 3.94 million new stroke cases, 28.76 million prevalent stroke cases, and 2.19 million deaths due to stroke in China in 2019 (Source: Data Management and Sharing System of the China National Clinical Research Center for Neurological Diseases). Furthermore, cases of Alzheimer’s disease are adding to the growing burden of neurological diseases in the country. According to a recent national cross-sectional study, China has 15.07 million individuals aged 60 years and over with dementia, which includes 9.83 million individuals with Alzheimer’s disease, 3.92 million individuals with vascular dementia, and nearly 1.32 million individuals with other forms of dementia. Thus, the increasing burden of neurological disorders is expected to boost the demand of advanced neurological solutions in the country

China Neurogenomics Market Opportunity

Technological Advancements in Neurogenomic Products

Need for genomic data increases with the increasing demand for next-generation sequencing. The huge volumes of data generated from NGS have created enormous pressure on healthcare providers in terms of data analysis, interpretation, reporting, and management. Data storage and computing tools save money and time while scaling production, keep data secure with monitoring by security and compliance, and easily share volumes of genomic data in multiple working groups with a user and team-specific access. Technological advancements in NGS informatics solutions have made it easier to create long sequencing runs, analyze sequencing data, monitor run status, and view results within shorter timeframes. Additionally, data flow from instruments can now be processed by software, making it easier to manage and analyze data using data analysis applications. NGS informatics technology has allowed the discovery of genetically targeted drugs and blood tests to detect cancer early. It has also enabled diagnoses for people with rare diseases. Thus, the technological advancements in sequencing solutions, is therefore expected to drive the growth of the China neurogenomics market.

Increasing Adoption of Targeted Therapies

Targeted therapies are increasingly adopted in neurogenomics studies for several factors which include their ability to target specific cells, increasing number of targeted therapies being approved by the FDA, and their efficacy and safety. Also, targeted therapies in neurogenomics can restrict the disease from progressing in the early phases. NGS has a major application in cancer diagnosis and targeted therapy based on biomarkers. The use of targeted therapy is expected to boost the growth of the market for neurogenomics solutions in the long run.

China Neurogenomics Market Analysis: Key Findings

The Next-generation sequencing (NGS) Segment to Dominate the China Neurogenomics Market in 2024

Based on offering, the China neurogenomics market is segmented into kits & reagents and systems. In 2024, the kits & reagents segment is expected to account for the largest share of 72.5% of the China neurogenomics market. The substantial market share of this segment is primarily driven by various factors such as recurring demand for consumables, increasing sequencing-based clinical and research neurogenomics applications, and growing preference for sequencing-based diagnostics are the factors supporting the large market share of this segment.

The Research Applications Segment to Dominate the China Neurogenomics Market in 2024

Based on applications, the China Neurogenomics Market is segmented into research applications and clinical applications. In 2024, the research applications segment is expected to account for the largest share of 61.4% of the China Neurogenomics Market. The research applications segment is further sub segmented into functional studies, target identification, variant discovery, and transcription factor binding analysis. NGS, PCR, and microarray solutions are extensively utilized in research to identify specific genes and their sequences to gain a better understanding of the mechanisms underlying complex neurological diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders. Such factors are expected to drive the growth of the market.

The Pharmaceutical & Biotechnology Companies Segment to Dominate the China Neurogenomics Market in 2024

Based on end user, the China Neurogenomics Market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, and academic & research institutes. In 2024, the pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of the China Neurogenomics Market. The large share of this segment is primarily attributed to the increasing adoption of advanced technologies for research purposes, the availability of capital, and increasing research for drug discovery with widening NGS applications, thereby accounting for the largest share of the market.

China Neurogenomics Market: Key Companies

The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last three to four years. Some of the key players operating in the China Neurogenomics Market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and MGI Tech Co., Ltd. (China).

China Neurogenomics Industry Overview: Latest Developments from Key Industry Players

• In January 2024, Illumina, Inc. (U.S.) partnered with Haplox, officially known as Shenzhen Hipros Biotechnology Co., Ltd (China), to develop and launch the NextSeq 2000 Dx CN-HAP, the first benchtop genetic sequencing technology of its kind.
• In March 2023, Illumina, Inc. (U.S.) launched Connected Insights, cloud-based software designed for tertiary analysis of clinical next-generation sequencing data. This platform supports applications in somatic oncology and whole genome sequencing for rare diseases and streamlines clinical reporting by integrating third-party knowledge bases, thereby reducing turnaround times.
• In October 2023, Thermo Fisher Scientific, Inc. (U.S.) acquired Olink Proteomics AB, a Sweden-based company specializing in advanced proteomics discovery and development. Olink operates across the Americas, Europe, and Asia Pacific, expanding Thermo Fisher's capabilities in the field of proteomics.
• In March 2022, Thermo Fisher Scientific, Inc. (U.S.) launched the Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing (NGS) platform capable of delivering results within a single day.

China Neurogenomics Market Research Summary

Key Questions Answered in the China Neurogenomics Market Report: